



LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY/PCN NO. 01994-0022		SERIAL NO. 08/586,427	FILING DATE January 16, 1996				
APPLICANT Lawrence Tamarkin et al.		GROUP <u>1806 1802</u>					
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>AB</i>	AA	4,740,589	04/26/88	Moreno			
	AB	3,145,144	08/18/64	Ando			
	AC	3,269,912	08/30/66	Grase			
	AD	3,577,523	05/04/71	Stolar et al.			
	AE	4,069,313	01/17/78	Woodhour et al.			
	AF	3,983,228	09/28/76	Woodhour et al.			
	AG	3,531,565	09/29/70	Webb et al.			
	AH	3,149,036	09/15/64	Woodhour et al.			
	AI	3,399,263	08/27/68	Strazdins et al.			
	AJ	4,657,763	04/14/87	Finkelstein			
<i>AK</i>	AK	4,330,530	05/18/82	Baker			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.	
<i>AL</i>	AL	WO 9102078	2/21/91	PCT			
	AM						
	AN						
	AO						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>AP</i>	AP	Fraker, et al., "Passive Immunization Against Tumor Necrosis Factor Partially Abrogates Interleukin 2 Toxicity," <i>The Journal of Experimental Medicine</i> , Vol. 170, pages 1015-1020 (1989)					
<i>AR</i>	AR	Lanzavecchia, "Identifying Strategies for Immune Intervention," <i>Science</i> , Vol. 260, pages 937-944 (1993)					
<i>AS</i>	AS	Paciotti, et al., "Interleukin 2 differentially effects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line <i>in vitro</i> and <i>in vivo</i> ," <i>Anti-Cancer Research</i> , Vol. 8, pages 1233-1240 (1988)					
<i>AT</i>	AT	Paciotti, et al., "Interleukin 1 differentially synchronizes estrogen dependent and estrogen-independent human breast cells in G ₀ /G ₁ phase of the cell cycle," <i>Anti-Cancer Research</i> , vol. 11, pages 25-32 (1991)					
EXAMINER <i>D Shaver</i>				DATE CONSIDERED <i>7/31/96</i>			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 01994-0022	SERIAL NO. 08/586,427	FILING DATE January 16, 1996
APPLICANT Lawrence Tamarkin et al.		GROUP 1806 1802

U.S. PATENT DOCUMENTS

EXAMINER INITIAL <i>GES</i>	DOCUMENT NUMBER BA	DATE 07/13/82	NAME Rosenberg et al.	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BB 4,177,263	12/04/79	Rosenberg et al.			
	BC 4,053,587	10/11/77	Davidson et al.			
	BD 4,977,286	12/11/90	Nicolaou et al.			
	BE 5,017,687	05/21/91	Vahlne et al.			
	BF 4,812,556	04/14/89	Vahlne et al.			
	BG 4,880,750	11/14/89	Francoeur			
	BH 5,035,995	07/30/91	Taguchi et al.			
	BI 4,882,423	11/21/89	Taguchi et al.			
	BJ 4,906,564	03/06/90	Lyon et al.			
	BK 5,019,497	05/28/91	Olsson			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.
BL					
BM					
BN					
BO					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>GES</i>	BP	Paciotti, et al., "Interleukin 1 directly regulates hormone-dependent human breast cancer cell proliferation <i>in vitro</i> ," <i>Mol. Endocrinol.</i> , Vol. 2, pages 459-464 (1988)
	BR	Coulombe et al., "Cytochemical Demonstration of Increased Phospholipid Content in Cell Membranes in Chlorphrntermine-induced Phospholipidosis," <i>Journal of Histochemistry and Cytochemistry</i> , Vol. 37, No. 2, pages 139-147 (1989)
	BS	Hashimoto et al., "Action Site of Circulating Interleukin-1 on the Rabbit Brain," <i>Brain Research</i> , Vol. 540, pages 217-223 (1991)
	BT	Ohmann et al., "Expression of Tumor Necrosis Factor- α Receptors on Bovine Macrophages, Lymphocytes and Polymorphonuclear Leukocytes, Internalization of Receptor-Bound Ligand, and Some Functional Effects," <i>Lymphokine Research</i> , Vol. 9, No. 1, pages 43-58 (1990)

EXAMINER <i>Q Shaver</i>	DATE CONSIDERED <i>7/3/96</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.		SERIAL NO.	FILING DATE					
01994-0022		08/586,427	January 16, 1996					
APPLICANT							GROUP	
Lawrence Tamarkin et al.		<i>1896 1802</i>						
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
GJ	CA	4,753,873	06/28/88	Beltz et al.				
	CB	4,744,760	05/17/88	Molday				
	CC	4,624,923	11/25/86	Margel				
	CD	3,651,211	03/21/72	Gillchrist et al.				
	CE	2,768,958	10/30/56	Stewart et al.				
	CF	2,785,153	03/12/57	Locke et al.				
	CG	3,819,820	06/25/74	Lorina et al.				
↓	CH	5,112,606	5/12/92	Shiosaka et al.				
	CI							
	CJ							
	CK							
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION		
	CL					YES	NO	
	CM							
	CN							
	CO							
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
	CP							
	CR							
	CS							
	CT							
EXAMINER				DATE CONSIDERED				
<i>J. Shaw</i>				<i>7/3/96</i>				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								